Much evidence demonstrates that pharmaceutical innovation is having a positive impact on short- and long-term improve- ments on human health. Novel drugs and/or their combina- tions, vaccines against communicable and non-communica- ble diseases (e.g. cancer, diabetes, and orphan diseases) are being introduced at an increasingly rapid pace. Furthermore, the use of the state-of the art technologies such as nanotech- nology and the application of new biomaterials are emerging [1]. The World Health Organization (WHO) has promoted the concept of health innovation to achieve universal health coverage within the context of its Sustainable Development Goals (SDGs). As part of this approach, the WHO adopted
The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI) to pro- mote a completely new approach to innovation and access to medicines. The WHO plan seeks to provide an enhanced and sustainable basis for needs-driven essential health research and development relevant to diseases that disproportionately affect developing countries
